Radboud University Nijmegen (NL)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
113
Publications
1764
Citations
86455
i10-index
626
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Combined Nivolumab and Ipilimumab or Monotherapy i... | 2015 | 8028 |
Overall Survival with Combined Nivolumab and Ipili... | 2017 | 5326 |
Nivolumab in Previously Untreated Melanoma without... | 2014 | 5302 |
Five-Year Survival with Combined Nivolumab and Ipi... | 2019 | 3619 |
Dabrafenib in BRAF-mutated metastatic melanoma: a ... | 2012 | 2950 |
Improved Overall Survival in Melanoma with Combine... | 2014 | 2613 |
Adjuvant Nivolumab versus Ipilimumab in Resected S... | 2017 | 2169 |
Improved Survival with MEK Inhibition in BRAF-Muta... | 2012 | 2128 |
Adjuvant Pembrolizumab versus Placebo in Resected ... | 2018 | 1810 |
Soft tissue and visceral sarcomas: ESMO–EURACAN Cl... | 2018 | 1597 |
Piotr Rutkowski is a researcher with 1764 publications and 86455 citations. They are affiliated with Radboud University Nijmegen. Their research focuses on . With an h-index of 113, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Piotr Rutkowski and 250M+ other papers.
Citations per publication by year